Daniel H Bedinger

USPTO Granted Patents = 16 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 68(Granted Patents)

Location History:

Vacaville, CA (US) (2011 - 2018)
Berkeley, CA (US) (2013 - 2019)
Emeryville, CA (US) (2023)
Pleasant Hill, CA (US) (2019 - 2024)

Company Filing History:

Musc Foundation for Research Development

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12234285 - Antibodies that bind interleukin-2 and uses thereof (2025-02-25),

2. 12071475 - Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment (2024-08-27),

3. 11787876 - Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof (2023-10-17),

4. 11098111 - Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3 (2021-08-24),

5. 10858428 - Antibodies that bind interleukin-2 and uses thereof (2020-12-08),

6. 10519250 - Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof (2019-12-31),

7. 10358486 - Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-β (2019-07-23),

8. 10253101 - Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia (2019-04-09),

9. 9885711 - Screening methods (2018-02-06),

10. 9714285 - TGF-beta-specific antibodies and methods of use thereof for treatment (2017-07-25),

11. 9145458 - Antibodies specific for TGF-β and methods of treatment thereof (2015-09-29),

12. 9005614 - PRLR-specific antibody and uses thereof (2015-04-14),

13. 8569462 - Antibodies specific for TGF-beta and methods for treating thereof (2013-10-29),

14. 8546308 - Triple tag sequences and methods of use thereof (2013-10-01),

15. 8546307 - Triple tag sequence and methods of use thereof (2013-10-01),

Certainly! Here is the article about inventor Daniel H Bedinger:

Title: Unveiling the Innovations of Daniel H Bedinger from Berkeley, CA

Introduction:

Daniel H Bedinger, a prolific inventor based in Berkeley, CA, has been a trailblazer in the field of biopharmaceutical innovations. With an impressive portfolio of 14 patents to his name, Bedinger has made significant contributions to the realms of cancer treatment and ophthalmic disorders.

Latest Patents:

1. Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof: Bedinger's groundbreaking patent revolves around human antibodies targeting the parathyroid hormone receptor 1 (PTH1R), showcasing potential in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), and various hyperparathyroidism conditions.

2. Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2, and TGF-beta 3: Bedinger's recent patent focuses on antibodies specific to transforming growth factor beta (TGFβ1, TGFβ2, and TGFβ3), offering novel therapeutic avenues for cancer and related conditions.

Career Highlights:

Bedinger has notably lent his expertise to esteemed companies such as Xoma Technology Ltd. and Xoma (US) LLC, where his innovative spirit and scientific acumen have flourished. His strategic vision has spearheaded advancements in the biopharmaceutical sector, shaping the landscape of medical research and development.

Collaborations:

During his illustrious career, Bedinger has collaborated with visionaries in the field, including esteemed colleagues Amer M Mirza and Toshihiko Takeuchi. Together, they have synergized their talents to drive forward cutting-edge research initiatives and bring novel solutions to fruition.

Conclusion:

In conclusion, Daniel H Bedinger stands as a luminary in the realm of biopharmaceutical innovations, with a remarkable patent portfolio that underscores his transformative impact on medical science. His relentless pursuit of excellence and collaborative ethos continue to pave the way for groundbreaking discoveries that hold the promise of revolutionizing healthcare practices worldwide.

This text is generated by artificial intelligence and may not be accurate.